Aims Mounting evidence suggests infection, specifically Chlamydia pneumoniae, plays a role in atherosclerosis. We tested whether antibiotic treatment with the macrolide roxithromycin improves clinical outcome in patients with acute non-Q-wave coronary syndromes. Preliminary reports revealed a reduction in events in the roxithromycin group at 30 days. We now report the long-term follow-up results.
Introduction
Atherosclerosis develops in all arteries beginning the moment we are born. The natural evolution of the atherosclerotic process is a progressive growth of arterial plaques. Accelerated atherosclerosis, however, alters the natural course of this degenerative process and may result in arterial thrombosis [1] . During the past 50 years enormous effort has been dedicated to modifying risk factors associated with increased rates of cardiovascular death. Interestingly, at least 50% of patients who suffer an acute myocardial infection have no identifiable risk factor, suggesting many risks remain undiscovered [2] . The vasodilatory and antithrombotic properties of endothelial cells are constantly challenged by normal physiological events. Transient post-prandial elevations in serum cholesterol and glucose, elevated blood pressure, nicotine exposure, and infection can damage the endothelium. Alone, these have a minor effect, but over a lifetime of continual exposure, they can severely impair the normal function of the endothelial cells. Chronic, low level stimuli begin the inflammatory process by attracting and facilitating inflammatory cell passage through the endothelium into the vessel's intimal layer, thereby initiating endothelial cell injury [3] . Atherosclerotic plaques contain a significant number of T-cell lymphocytes and macrophages [4] [5] , some of which are dedicated to lipid scavenging, while others express the major histocompatability complex molecule HLA-DR and co-stimulatory molecules necessary for an immune response [6] . The evidence of an active immune response, Revision submitted 24 July 1998, and accepted 29 July 1998. perhaps against infectious pathogens, motivated the ROXIS study [7] , whose preliminary report showed that using a non-traditional therapy, the macrolide antibiotic roxithromycin, can change the outcome of patients admitted with unstable angina and acute non-Q-wave myocardial infarction.
Current antithrombotic strategies show a clinical benefit during active treatment, but a loss of efficacy during long-term follow-up [8] . We now present the results of the long-term follow-up of patients enrolled in the ROXIS Study.
Methods

Study design and treatment protocol
The ROXIS Study design was published elsewhere [7] . At admission, all patients with recent onset of angina at rest, lasting at least 10 min, and occurring within 48 h before randomization met criteria for inclusion and were treated with 100-325 mg aspirin daily, intravenous nitroglycerin, unfractionated heparin (with the dose adjusted to give an activated partial thromboplastin time of 1·9-2·5 ties baseline) for a minimum of 72 h and a maximum of 8 days; beta-blockers or calcium channel blockers were administered when appropriate.
After initiating conventional therapy and obtaining informed consent, patients were randomized to receive either roxithromycin 150 mg twice daily or matching placebo twice daily for 30 days. (Roxithromycin is a second-generation macrolide antibiotic approved in many western nations to treat chlamydial infections). Follow-up visits were scheduled at day 31, day 90, and 6 months post-treatment with serum collected at enrolment and day 31.
Primary and secondary efficacy assessments and end-point definitions
Severe recurrent ischaemia is confirmed if chest pain lasts at least 5 min with ST-T changes in at least two contiguous leads (ST elevation or depression d0·1 mV and/or T-wave inversion) provoking re-hospitalization and/or prompting a decision to revascularize within 24 h following the event. Acute myocardial infarction is confirmed if creatinine kinase-MB (and at least 3% of total creatinine kinase) is elevated above normal, or if creatine kinase is twice the upper limit of normal, plus chest pain lasting 5 min or more followed by the appearance of new significant Q waves (d0·03 s) in at least two leads in the ECG. Death was attributed to cardiac ischaemia.
The composite double end-point was defined as death plus acute myocardial infarction and the composite triple end-point as death, acute myocardial infarction, and recurrent ischaemia.
Serological assessments
Blood samples for serological assessment and C-reactive protein determinations were submitted from the participant sites to a central laboratory.
Serological response
Serum IgG titres against C. pneumoniae-specific antibodies were measured at baseline and day 31. Whole inactivated (formalin fixed) organisms derived from TWAR strain AR 39 (Fuller Laboratories, U.S.A.) with fluorescence labelled anti-human IgG globulins (bio Mérieux, S.A. France) were used in a microimmunofluorescence assay. A titre greater than or equal to 1:64 was considered positive.
Inflammatory response C-reactive protein levels were determined quantitatively by immuno-turbidimetry (Turbiquant, Behringerwerke AG, Germany) at baseline and day 31. Positive results were defined as d0·5 mg . dL 1 .
Statical analysis
The primary analysis included all randomized patients in an intention-to-treat basis. The P value indicating statistical significance for the primary and secondary end-point was set at 0·05. If more than one end-point was observed in the same patient, the Data Review Board Committee assigned the severity of the event in the following sequence: severe recurrent ischaemia, myocardial infarction, death. The analysis of the primary clinical end-points (ischaemic death, acute myocardial infarction, and severe recurrent ischaemia) occurring after a period of 72 h (six doses) and up to day 31 have been published elsewhere [7] . The analysis of the secondary clinical end-points (ischaemic death, acute myocardial infarction and recurrent ischaemia) was performed at day 90 and 6 months.
Preliminary power analysis, based on an expected 14% incidence of the composite end-point at 30 days and a 20% reduction in events in the active group, indicated that a total of 3946 patients would be required. Given the magnitude of this sample size and the lack of prior evidence of antibiotic efficacy in terms of risk reduction, a pilot study was justified.
Results
Of the 205 patients recruited into the study, three failed to meet the inclusion criteria. The remaining 202 eligible patients were assigned to roxithromycin therapy (n=102) or placebo (n=100) through the randomization process (intent-to-treat analysis). A secondary analysis was performed on the data from the 186 patients who completed at least 72 h (six doses) of study treatment. Nine patients in the roxithromycin arm and seven in the placebo arm did not complete the minimum 3 days of treatment due to emergency coronary artery bypass graft surgery (CABG) (n=7), the need for other antibiotic therapy (n=2), or lack of compliance or withdrawal of consent (n=7).
Among patients who completed the minimum 3 days of treatment, 63 (67·7%) of the placebo-treated group and 66 (70·2%) of the roxithromycin-treated group completed the entire 30-day treatment period. The mean length of treatment in both the placebo and roxithromycin groups was 24 days.
Baseline characteristics
Baseline characteristics shown in Table 1 have been published elsewhere [7] . A discharge diagnosis of non-Qwave myocardial infarction was given to 11% of patients treated with roxithromycin and 9% of the placebotreated group. A total of 188 (93%) patients completed 6 months of follow-up (14 patients withdrew their informed consent or chose to end their study participation at their own physicians suggestion).
Clinical results
Intention-to-treat analysis
The primary clinical end-point was assessed at day 30, with patients randomized to the roxithromycin arm demonstrating a reduction of triple combined events (unadjusted P=0·032). At 90 and 180 days, the active group continued having a lower rate of events (unadjusted P=0·065 and unadjusted P=0·259, respectively) ( Table 2) .
Double secondary end-point rates again showed a trend towards fewer events in the roxithromycin group at day 30 (unadjusted P=0·058), day 90 (unadjusted P=0·029), and day 180 (unadjusted P=0·17). (Table 2) .
Analysis of patients receiving a minimum of 72 h of study drug
The primary triple end-point rate was reduced in the active treatment arm at day 30 (unadjusted P=0·018), 
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day 90 (unadjusted P=0·029), and day 180 (unadjusted P=0·167). The double end-points were also reduced in the roxithromycin group at day 30 (unadjusted P=0·121), day 90 (unadjusted P=0·029), and day 180 (unadjusted P=0·171) ( Table 3 ). Figure 1 shows the time to final event estimation (death, myocardial infarction, or severe recurrent angina) in the 180 days after randomization in both groups.
Adverse reactions
Three patients experienced a mild skin reaction (two in the roxithromycin group and one in the placebo group).
One patient randomized to placebo experienced vomiting during the active treatment period and another nausea. All of the events were considered non-serious.
Electrocardiographic analysis
Patients' electrocardiograms (ECG) at the end of active treatment were analysed because macrolide antibiotics have been associated with prolonged QT intervals, inducing torsade de pointes or ventricular tachycardia. After the active treatment period, the mean QT interval was unchanged in both groups, with no difference between treatment groups (0·41 s, SD 0·04 min, 0·32-max. 0·51 in placebo group vs 0·41 s, SD 0·04, min 0·34-max 0·52 in active arm, P=0·14).
Serological analyses IgG titres
Under the intention-to-treat basis, the percentage of patients with anti-C. pneumoniae IgG titres d1:64 increased slightly in the placebo group between baseline and day 30 (P=0·22), while remaining unchanged in the roxithromycin group. No statistically significant differences in titre dilution were seen between the groups at baseline or day 31. Among patients who received the minimum 72 h of treatment, there was again no difference between groups in IgG titres at baseline or at day 31. Ischaemic events occurred more frequently among patients with higher IgG titres independent of the study therapy (13·9% vs 7·2%, P=0·315). In this pilot study we were unable to demonstrate an association between the efficacy of roxithromycin therapy and IgG titres.
C-reactive protein
Baseline C-reactive protein levels were tested in 160 patients (Table 4) . Levels decreased in both groups at day 30, although the decline did not reach statistical significance. A significantly greater number of patients in the roxithromycin group experienced a decrease in C-reactive protein levels after treatment than in the placebo group. C-reactive protein levels in patients with a positive response fell from 53·7% to 35·8% at day 31 in the roxithromycin group vs 47·4% to 31·3% in the placebo group (P=0·03). High baseline levels of C-reactive protein were not associated with major ischaemic events in either group, but positive C-reactive protein levels were related to a need for urgent or programmed CABG or percutaneous transluminal coronary angioplasty, irrespective of randomization (42% revascularization rate if C-reactive protein was positive vs 20·3% if negative, P=0·005).
Patients with positive IgG titres and elevated C-reactive protein were more likely to experience a recurrent ischaemic event than those with negative IgG titres and low C-reactive protein levels (43% vs 9·1%; P=0·027).
Discussion
In recent years, growing evidence has implicated infectious agents [9] specifically C. pneumoniae and cytomegalovirus [10] . in the development of atherosclerosis and post-angioplasty restenosis.
The evidence linking C. pneumoniae to atherosclerosis rests on both indirect observations, such as the reduction in cardiovascular events coinciding with widespread antibiotic use [11] , direct serological [12, 13] and pathological [14] studies, as well as on experimental animal models of C. pneumoniae-induced atherogenesis [15, 16] . The mounting evidence for an infectious component in atherosclerotic lesions highlights the necessity for clarifying, through clinical trials, the potential role of antibiotics in coronary artery disease [17] . The preliminary ROXIS Study [7] reported a significant reduction in ischaemic events during the active treatment period in patients given the antibiotic roxithromycin compared to standard aspirin therapy. These results could be attributed to chance, given the size of the pilot study, but the number and distribution of the events occurring during the first 30 days in the placebo group (44% within the first 6 days and 56% between day 6 and 30) are consistent with known rates of coronary events and therefore tend to discount the role of mere probability. In the present report, the rate of events at day 90 suggest that antibiotics had a residual effect. This trend (no longer significant) appears to be sustained until 6 months after study treatment termination. This loss of statistical power may be attributed to the short period of treatment, (which is not yet established), the potential for re-infection by C. pneumoniae during the follow-up period, and finally, the relative small number of events during the trial.
Results consistent with our study were reported by Gupta et al. [18] . Like ourselves this group also found a lower incidence of ischaemic events and need for revascularization in post-myocardial infarction patients from South London, who received a macrolide antibiotic compared to patients receiving placebo. This study was designed to investigate changes in antichlamydial antibodies. Patients receiving azithromycin showed a significant decrease in titres of IgG antibodies that indicate a chronic infection, compared to no change in titres of control patients. The decrease in titres, however, is difficult to interpret given the irregular behaviour of immunological markers in C. pneumoniae infection, which tend to decrease years after an initial infection.
In contrast, anti-C. pneumoniae antibody titres in the ROXIS Study were not affected, at least during the active treatment period, by the action of antibiotics, and followed immunological patterns that were assumed at the beginning of the study. 
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The ROXIS was a multicentre study conducted at hospitals from diverse communities, with the aim of proving the widespread prevalence of this intracellular pathogen. Moreover, the practice of enrolling patients independent of baseline titres was confirmed by the results: these revealed no difference in outcome related to baseline IgG titres. The actions of antibiotics, independent of baseline antibody titres, suggest that IgG titres may not be an adequate marker for guiding treatment therapy [19] . Given the relatively small number of events occurring during the study, as well as the total sample size, one cannot evaluate whether the ischaemic events observed were associated with an acute reinfection, which is common in C. pneumoniae, or a chronic infection.
The immune system is capable of unleashing a powerful inflammatory reaction when stimulated by chlamydia-like bacterial proteins [20] , lipopolysaccharides [21] , as well as antigens such as heat shock proteins that trigger a humoral and cellular immune reaction [22, 23] . During the ROXIS study we evaluated the inflammatory response through C-reactive protein concentrations in plasma. C-reactive protein levels were not a predictor of primary clinical events, but elevated baseline levels were found in those patients who eventually required a revascularization procedure.
If indeed C-reactive protein is a sensitive but non-specific marker of inflammation, then antibiotics apparently do have an influence on their level. C-reactive protein levels decreased in both groups after the treatment period, although with a significantly greater decrease in the active treatment arm. A potential anti-inflammatory effect of macrolide antibiotics beyond their bactericidal action [24] remains uncertain and may require different markers of inflammation to evaluate. To achieve an 80% statistical power, we would have required close to 4000 patients. This trial was thus designed as a pilot study to test the hypothesis that antibiotics may be effective in atherosclerotic diseases. Several clinical studies, in various stages of development, will help determine if infection plays an important role in both the unstable, as well as the quiescent phase, of atherosclerosis. If these new studies are consistent with the findings of ROXIS, future therapy for atherosclerotic disease, instead of including more cardiac drugs per patient, may become tailored to a patient's individual risk profile. Preventing the development and instability of atherosclerosis, perhaps with treatment that includes a vaccine against C. pneumoniae, will be the eventual goal in atherosclerotic diseases.
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